Thymosin β4-mediated protective effects in the heart

References

• Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
   PubMed Web of Science ®Google Scholar
• DALYs GBD, Collaborators, H. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603–1658.
   PubMed Web of Science ®Google Scholar
• Mortality GBD, Causes of Death, C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544.
   PubMed Web of Science ®Google Scholar
• Writing Group, M, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.
   PubMed Web of Science ®Google Scholar
• Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. MolTher. 2007;15:1233–1247.
   Google Scholar
• Grazioli A, Alves CS, Konstantopoulos K, et al. Defective blood vessel development and pericyte/pvSMC distribution in alpha 4 integrin-deficient mouse embryos. DevBiol. 2006;293:165–177.
   Google Scholar
• Garmy-Susini B, Jin H, Zhu Y, et al. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. JClinInvest. 2005;115:1542–1551.
   PubMed Web of Science ®Google Scholar
• Deindl E, Schaper W. The art of arteriogenesis. Cell BiochemBiophys. 2005;43:1–15.
   Google Scholar
• Yla-Herttuala S, Baker AH. Cardiovascular gene therapy: past, present, and future. Mol Therapy: Journal Am Soc Gene Ther. 2017;25:1095–1106.
   PubMed Web of Science ®Google Scholar
• Kupatt C, Hinkel R, Pfosser A, et al. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. JAmCollCardiol. 2010;56:414–422.
   Web of Science ®Google Scholar
• Banquet S, Gomez E, Nicol L, et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation. 2011;124:1059–1069.
   PubMed Web of Science ®Google Scholar
• Tao Z, Chen B, Tan X, et al. Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. Proc Natl Acad Sci U S A. 2011;108:2064–2069.
   PubMed Web of Science ®Google Scholar
• Klein JJ, Goldstein AL, White A. Effects of the thymus lymphocytopoietic factor. AnnNYAcadSci. 1966;135:485–495.
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Guha A, Zatz MM, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. ProcNatlAcadSciUSA. 1972;69:1800–1803.
   PubMed Web of Science ®Google Scholar
• Huff T, Muller CS, Otto AM, et al. beta-Thymosins, small acidic peptides with multiple functions. IntJBiochemCell Biol. 2001;33:205–220.
   Google Scholar
• Hannappel E. beta-Thymosins. AnnNYAcadSci. 2007;1112:21–37.
   PubMed Web of Science ®Google Scholar
• Huang WQ, Wang QR. Bone marrow endothelial cells secrete thymosin beta4 and AcSDKP. ExpHematol. 2001;29:12–18.
   PubMed Web of Science ®Google Scholar
• Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466–472.
   PubMed Web of Science ®Google Scholar
• Ballweber E, Hannappel E, Huff T, et al. Polymerisation of chemically cross-linked actin: thymosinbeta(4) complex to filamentous actin: alteration in helical parameters and visualisation of thymosin beta(4) binding on F-actin. JMolBiol. 2002;315:613–625.
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends MolMed. 2005;11:421–429.
   PubMed Web of Science ®Google Scholar
• Grant DS, Kinsella JL, Kibbey MC, et al. Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. JCell Sci. 1995;108(Pt 12):3685–3694.
   PubMedGoogle Scholar
• Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11:474–481.
   PubMed Web of Science ®Google Scholar
• Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18:385–387.
   PubMedGoogle Scholar
• Gomez-Marquez J, Franco Del AF, Carpintero P, et al. High levels of mouse thymosin beta4 mRNA in differentiating P19 embryonic cells and during development of cardiovascular tissues. BiochimBiophysActa. 1996;1306:187–193.
   PubMedGoogle Scholar
• Shin SH, Lee S, Bae JS, et al. Thymosin beta4 regulates cardiac valve formation via endothelial-mesenchymal transformation in zebrafish embryos. Mol Cells. 2014;37:330–336.
   PubMed Web of Science ®Google Scholar
• Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445:177–182.
   PubMed Web of Science ®Google Scholar
• Rossdeutsch A, Smart N, Dube KN, et al. Essential role for thymosin beta4 in regulating vascular smooth muscle cell development and vessel wall stability. Circ Res. 2012;111:e89–e102.
   PubMed Web of Science ®Google Scholar
• Banerjee I, Moore Morris T, Evans SM, et al. Thymosin beta4 is not required for embryonic viability or vascular development. Circ Res. 2013;112:e25–e28.
   PubMed Web of Science ®Google Scholar
• Banerjee I, Zhang J, Moore-Morris T, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. CircRes. 2012;110:456–464.
   Web of Science ®Google Scholar
• Smart N, Riegler J, Turtle CW, et al. Aberrant developmental titin splicing and dysregulated sarcomere length in Thymosin beta4 knockout mice. J Mol Cell Cardiol. 2017;102:94–107.
   PubMed Web of Science ®Google Scholar
• Bock-Marquette I, Shrivastava S, Pipes GC, et al. Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. JMolCell Cardiol. 2009;46:728–738.
   Google Scholar
• Ziegler T, Hinkel R, Stohr A, et al. Thymosin beta4 improves differentiation and vascularization of EHTs. Stem Cells Int. 2017;2017:6848271.
   PubMedGoogle Scholar
• Zimmermann WH, Fink C, Kralisch D, et al. Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol Bioeng. 2000;68:106–114.
   PubMed Web of Science ®Google Scholar
• Zimmermann WH, Schneiderbanger K, Schubert P, et al. Tissue engineering of a differentiated cardiac muscle construct. Circ Res. 2002;90:223–230.
   PubMed Web of Science ®Google Scholar
• Breckwoldt K, Letuffe-Breniere D, Mannhardt I, et al. Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nat Protoc. 2017;12:1177–1197.
   PubMed Web of Science ®Google Scholar
• Srivastava D, Ieda M, Fu J, et al. Cardiac repair with thymosin beta4 and cardiac reprogramming factors. Ann N Y Acad Sci. 2012;1270:66–72.
   PubMed Web of Science ®Google Scholar
• Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012;485:593–598.
   PubMed Web of Science ®Google Scholar
• Peng H, Xu J, Yang XP, et al. Thymosin-beta4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction. American Journal Physiology Heart Circulatory Physiology. 2014;307:H741–H751.
   PubMed Web of Science ®Google Scholar
• Kumar A, Patel A, Duvalsaint L, et al. Thymosin beta4 coated nanofiber scaffolds for the repair of damaged cardiac tissue. J Nanobiotechnology. 2014;12:10.
   PubMed Web of Science ®Google Scholar
• Choudry FA, Yeo C, Mozid A, et al. Increases in plasma Tbeta4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement. Regen Med. 2015;10:403–410.
   PubMed Web of Science ®Google Scholar
• Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circ. 2008;117:2232–2240.
   PubMed Web of Science ®Google Scholar
• Grillon C, Rieger K, Bakala J, et al. Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Letters. 1990;274:30–34.
   PubMed Web of Science ®Google Scholar
• Rieger KJ, Saez-Servent N, Papet MP, et al. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem J. 1993;296(Pt 2):373–378.
   PubMedGoogle Scholar
• Yang F, Yang XP, Liu YH, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension (Dallas, Tex: 1979). 2004;43:229–236.
   PubMed Web of Science ®Google Scholar
• Hinkel R, Ball HL, DiMaio JM, et al. C-terminal variable AGES domain of Thymosin beta4: the molecule’s primary contribution in support of post-ischemic cardiac function and repair. J Mol Cell Cardiol. 2015;87:113–125.
   PubMed Web of Science ®Google Scholar
• Stark CK, Tarkia M, Kentala R, et al. Systemic dosing of Thymosin Beta 4 before and after ischemia does not attenuate global myocardial ischemia-reperfusion injury in pigs. Front Pharmacol. 2016;7:115.
   PubMed Web of Science ®Google Scholar
• Drum CL, Tan WKY, Chan SP, et al. Thymosin Beta-4 is elevated in women with heart failure with preserved ejection fraction. J Am Heart Assoc. 2017;6.
   PubMed Web of Science ®Google Scholar
• Bicer A, Karakurt O, Akdemir R, et al. Thymosin beta 4 is associated with collateral development in coronary artery disease. ScandJClinLab Invest. 2011;71:625–630.
   PubMed Web of Science ®Google Scholar
• Hinkel R, Trenkwalder T, Petersen B, et al. MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2. Nat Commun. 2014;5.
   PubMed Web of Science ®Google Scholar
• Ziegler T, Kraus M, Husada W, et al. Steerable induction of the Thymosin beta4/MRTF-A pathway via AAV-based overexpression induces therapeutic neovascularization. Hum Gene Ther. 2017.
   PubMedGoogle Scholar
• Stieger K, Belbellaa B, Le Guiner C, et al. In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev. 2009;61:527–541.
   PubMed Web of Science ®Google Scholar
• WHO Global report on diabetes. 2016.
   Google Scholar
• Rawshani A, Rawshani A, Franzen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–1418.
   PubMed Web of Science ®Google Scholar
• Renner S, Braun-Reichhart C, Blutke A, et al. Permanent neonatal diabetes in INSC94Y transgenic pigs. Diabetes. 2013;62:1505–1511.
   PubMed Web of Science ®Google Scholar
• Renner S, Fehlings C, Herbach N, et al. Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes. 2010;59:1228–1238.
   PubMed Web of Science ®Google Scholar
• Wolf E, Braun-Reichhart C, Streckel E, et al. Genetically engineered pig models for diabetes research. Transgenic Res. 2014;23:27–38.
   PubMed Web of Science ®Google Scholar
• Hinkel R, Hoewe A, Renner S, et al. Diabetes mellitus-induced microvascular destabilization in the myocardium. J Am Coll Cardiol. 2017;69:131–143.
   PubMed Web of Science ®Google Scholar
• Raake P, Von DG, Hinkel R, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. JAmCollCardiol. 2004;44:1124–1129.
   Web of Science ®Google Scholar
• Raake PW, Hinkel R, Muller S, et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther. 2008;15:12–17.
   PubMed Web of Science ®Google Scholar
• Hinkel R, Howe A, Renner S, et al. Diabetes mellitus-induced microvascular destabilization in the myocardium. J Am Coll Cardiol. 2017;69:131–143.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circ. 2010;121:e46–e215.
   PubMed Web of Science ®Google Scholar
• Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. JAmCollCardiol. 2001;38:409–414.
   Web of Science ®Google Scholar
• White HD, Chew DP. Acute myocardial infarction. Lancet. 2008;372:570–584.
   PubMed Web of Science ®Google Scholar
• Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–350.
   PubMed Web of Science ®Google Scholar
• Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. NEnglJMed. 2002;347:1397–1402.
   PubMed Web of Science ®Google Scholar
• Pedrazzini G, Santoro E, Latini R, et al. Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI)-3 trial. AmHeart J. 2008;155:388–394.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. CircHeart Fail. 2013;6:606–619.
   Google Scholar
• Kannel WB. The Framingham Study: ITS 50-year legacy and future promise. J Atheroscler Thromb. 2000;6:60–66.
   PubMedGoogle Scholar
• Henderson RA, Jarvis C, Clayton T, et al. 10-year mortality outcome of a routine invasive strategy versus a selective invasive strategy in Non–ST-Segment elevation acute coronary syndrome: the british heart foundation RITA-3 randomized trial. J Am Coll Cardiol. 2015;66:511–520.
   PubMed Web of Science ®Google Scholar
• De Luca G, Sauro R, Capasso M, et al. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction. Diabetes Vasc Dis Res. 2015;12:306–314.
   PubMed Web of Science ®Google Scholar
• Nyström T, Holzmann MJ, Eliasson B, et al. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. J Am Coll Cardiol. 2015;66:535–543.
   PubMed Web of Science ®Google Scholar
• Yan BP, Duffy SJ, Clark DJ, et al. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am J Cardiol. 2008;101:1716–1722.
   PubMed Web of Science ®Google Scholar
• Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114:101–108.
   PubMed Web of Science ®Google Scholar
• Guarnera G, De RA, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. AnnNYAcadSci. 2007;1112:407–412.
   PubMed Web of Science ®Google Scholar
• Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207–212.
   PubMed Web of Science ®Google Scholar
• Sosne G, Dunn SP, Kim C. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34:491–496.
   PubMed Web of Science ®Google Scholar
• Ruff D, Crockford D, Girardi G, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. AnnNYAcadSci. 2010;1194:223–229.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357–2365.
   PubMed Web of Science ®Google Scholar
• Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Therapy: Journal Am Soc Gene Ther. 2012;20:443–455.
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet. 2007;369:2097–2105.
   PubMed Web of Science ®Google Scholar
• Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circ. 2011;124:304–313.
   PubMed Web of Science ®Google Scholar
• Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387:1178–1186.
   PubMed Web of Science ®Google Scholar